Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk’s Hemophilia B Drug Faces Safety Scrutiny By US FDA Panel

Executive Summary

Novo’s long-acting coagulation Factor IX showed polyethylene glycol (PEG) accumulation in the choroid plexus of animals, potentially raising a neurological safety issue when used in humans, FDA says ahead of Blood Products Advisory Committee review.

Advertisement

Related Content

Novo Nordisk Gets Approval For Hemophilia B Treatment Sans Postmarketing Requirements
Novo Hemophilia Drug's Postmarket Monitoring Plan Not Robust Enough – US Panel
CHMP’s March Recommendations Include Dinutuximab, Nonacog Beta Pegol And Trumenba
Keeping Track: Tecentriq, Opdivo Approvals Intensify Spotlight On Immuno-Oncology
CSL Behring's Hemophilia B Drug May Have Dosing Advantage
Biogen Plays It Safe With Pricing Of Hemophilia Drug Alprolix

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS120355

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel